FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely neurology, and concerns treating multiple sclerosis. That is ensured by the oral introduction of the S1P receptor modulator representing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof in a daily dose of 0.5 mg.
EFFECT: invention provides preventing or reducing the intensity of recurrences of remittent-recurrent multiple sclerosis.
6 cl
| Title | Year | Author | Number |
|---|---|---|---|
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
| LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
| LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| USING SIP RECEPTOR MODULATORS IN OPHTHALMOLOGY | 2006 |
|
RU2497513C2 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
| SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR MODULATORS AND USING THEM FOR TREATING MUSCULAR TISSUE INFLAMMATION | 2009 |
|
RU2521286C2 |
